Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

NCT03969329 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03969329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
December 20, 2019
Completion date
June 30, 2027
Enrollment
24 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism